Trials / Terminated
TerminatedNCT03656640
Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases
A Prospective, Multicenter Observational Trial Assessing the Safety and Efficacy of Gammanorm® in Autoimmune Diseases
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational trial assesses the safety and efficacy of Gammanorm® in autoimmune diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gammanorm | Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care. |
Timeline
- Start date
- 2016-11-23
- Primary completion
- 2019-12-09
- Completion
- 2019-12-09
- First posted
- 2018-09-04
- Last updated
- 2021-03-10
Locations
3 sites across 2 countries: France, Martinique
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03656640. Inclusion in this directory is not an endorsement.